Long-term studies with the new potassium-sparing diuretic, amiloride (‘MK-870’)
| Autor: | Michael Byrne, T. B. Counihan, Andrew G. A. Heffernan |
|---|---|
| Rok vydání: | 1969 |
| Předmět: |
Adult
Male Drug medicine.medical_specialty Heart Diseases medicine.drug_class media_common.quotation_subject Thiazide diuretic Potassium chemistry.chemical_element Hypokalemia Electrolytes Internal medicine Methods medicine Humans Diuretics media_common business.industry General Medicine Hydrogen-Ion Concentration Middle Aged Water-Electrolyte Balance Total body potassium Amiloride Endocrinology Serum potassium chemistry Pyrazines Potassium-sparing diuretic Female business medicine.drug |
| Zdroj: | Irish Journal of Medical Science. 2:3-16 |
| ISSN: | 0021-1265 |
| DOI: | 10.1007/bf02954667 |
| Popis: | (1) Short term studies in five subjects show that amiloride is a potassiumsparing natriuretic agent alone and with thiazide diuretic and ethacrynic acid even when the dose is 5 mg. (2) There was no loss of potassium-sparing effect in four patients receiving the drug continuously for a period of fifteen months or more. (3) Hyperkalaemia did not occur but this is a potential hazard and so regular estimation of the serum potassium is necessary, though this does not give accurate information of the total body potassium. Also, potassium supplements should not be used with amiloride. (4) No serious side effects or toxic reactions were found in this study or by other workers. (5) Amiloride is unlikely to prevent diuretic-induced hyperuricaemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink